A Phase 3 interventional study of tafamidis in ATTR-CM and TTR-CM, sponsored by Pfizer. Completed at 7 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-01-05.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 230 studies in Cardiomyopathies with a site in United States — 56 open to participants now, 68 under way, 6 of them phase 3. Cardiomyopathies · United States.
Among the 230 studies in Cardiomyopathies with a site in United States, this one is the 78th largest by enrollment of the 132 interventional ones that give a count, is one of 6 that started in 2009, is one of 18 in phase 3, and was the 56th registered.
553 studies on the registry are indexed under Cardiomyopathies; 151 are open to participants now.
Browse Cardiomyopathies studies →56 of the 230 studies in Cardiomyopathies with a site in United States are open now. Recruiting first, the newest first:
Atrium Therapeutics · Sites in United States
Ages 18–65
Vanderbilt University Medical Center · Sites in United States
Ages 8–18 · Men only
Old Dominion University · Sites in United States
Ages 18–85
Eidos Therapeutics, a BridgeBio company · Sites in United States
Ages 18–80
Lexeo Therapeutics · Sites in United States
Ages 6+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 115 Cardiomyopathies studies recruiting now, 70 (61%) set no upper age limit and 17 (15%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
230 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 29 · Phase 2 32 · Phase 3 20 · Phase 4 13
First in 1996; this study’s year is marked. 6 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 31 is below the median of 51 across 266 interventional studies indexed under Cardiomyopathies.
Median enrollment 42 across the 132 interventional studies, 160 across the 96 observational. Of the 139 that completed or were terminated, 65 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
72 of 230 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 5 studies filed under Cardiomyopathies — fewer than ten, so there is no comparison to draw.
17 of the studies in Cardiomyopathies with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06109181Lexeo TherapeuticsGene Therapy for ACM Due to a PKP2 Pathogenic Variant | 2026-12 |
| NCT04520347University of California, Los AngelesIVTCC 2.0: A Prospective Multicenter Ventricular Tachycardia Catheter Ablation Registry | 2026-12 |
| NCT04843371Tulane UniversityPPG to Predict Ejection Fraction and Other Echographic Data in the General Population | 2026-12 |
| NCT02855554Medical University of South CarolinaQuantitative Cardiac Parametric Mapping | 2026-12 |
| NCT03534726University of PennsylvaniaEdema and Fibrosis CMR Imaging in Cardiomyopathy | 2026-12-31 |
Add all 17 to your calendar (.ics) → With an account.
Among the 230 studies in Cardiomyopathies with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Open-label Safety and Efficacy Evaluation of Fx-1006a in Patients with V122i Or Wild-type Transthyretin (ttr) Amyloid Cardiomyopathy.
Patients who successfully complete Fx1B-201 will report to the clinical unit on Day 0 to sign the informed consent form and determine eligibility for Protocol Fx1B-303. In addition, on Day 0, patients will have their entrance criteria reviewed, and medical histories and demographic characteristics obtained.
The physical examination (including weight and vital signs) and the relevant end of study clinical laboratory tests (alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, blood urea nitrogen, gamma glutamyl transferase, creatinine, total bilirubin, international normalized ratio, troponin I, troponin T, and amino-terminal B-type natriuretic peptide) from Protocol Fx1B-201 will be used for Protocol Fx1B-303. If more than 30 days has elapsed between the final study visit of Protocol Fx1B-201 and Day 0 of Protocol Fx1B-303, an abbreviated physical examination (including weight and vital signs) and clinical laboratory assessments must be performed on Day 0.
Eligible patients will begin once-daily dosing with 20 mg Fx-1006A at home on Day 1 (i.e., first dose) and will return to the clinical unit for study visits every 6 months.
Adverse events (AEs) and concomitant medication use will be collected at each 6-month visit to the clinical unit. Blood draws for clinical safety laboratory tests and abbreviated physical examinations (including weight and vital signs) will also be performed at each 6-month clinic visit. ECGs will be performed every 12 months on an annual basis. A telephone call will be made at 3-month intervals between clinic visits to assess safety and use of concomitant medications.
For the evaluation of efficacy, the Patient Global Assessment, NYHA classification, KCCQ, 6-minute walk test, and efficacy-related clinical laboratory tests (serum levels of troponin T, troponin I, and NT-pro-BNP) will be determined every 6 months. In addition, echocardiograms will be performed every 12 months on an annual basis.
An end of study visit including all safety and efficacy assessments will occur upon patient completion of the study, premature withdrawal (for any reason), or in the event of program discontinuation by the Sponsor.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: tafamidis
Once daily 20 mg oral tafamidis (soft gelatin capsule)
Percentage of Participants With Categories of Patient Global Assessment (PGA) for Follow-up Visit: Month 12
Participants overall quality of life was measured by PGA. At follow-up visit, participants were asked, "How do you feel today as compared to when we talked with you at your last clinic visit for this study?" and participants responded to any of the following: markedly improved, moderately improved, mildly improved, unchanged, mildly worsened, moderately worsened or markedly worsened.
Time frame: Month 12
Percentage of Participants With Categories of Patient Global Assessment (PGA) for Follow-up Visit: Month 60
Participants overall quality of life was measured by PGA. At follow-up visit, participants were asked, "How do you feel today as compared to when we talked with you at your last clinic visit for this study?" and participants responded to any of the following: markedly improved, moderately improved, mildly improved, unchanged, mildly worsened, moderately worsened or markedly worsened.
Time frame: Month 60
Number of Participants Classified on the Basis of New York Heart Association (NYHA) Classification at Baseline
NYHA classified participants in 4 classes. Class I included participants with cardiac disease without limitations of physical activity. Ordinary physical activity did not cause undue fatigue, palpitation, dyspnea, or anginal pain. Class II included participants with cardiac disease with slight limitation of physical activity. They were comfortable at rest. Ordinary physical activity resulted in fatigue, palpitation, dyspnea, or anginal pain. Class III included participants with cardiac disease with marked limitation of physical activity. They were comfortable at rest. Less than ordinary physical activity caused fatigue, palpitation, dyspnea, or anginal pain. Class IV included participants with cardiac disease with the inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome might be present even at rest. If any physical activity was undertaken, discomfort was increased.
Time frame: Baseline
Number of Participants With Change From Baseline in New York Heart Association (NYHA) Classification at Month 12
NYHA classified participants in 4 classes: Class I: cardiac disease without limitations of physical activity. Ordinary physical activity caused no undue fatigue, palpitation, dyspnea or angina pain. Class II: cardiac disease with slight limitation of physical activity, comfortable at rest. Ordinary physical activity resulted in fatigue, palpitation, dyspnea or angina pain. Class III: cardiac disease with marked limitation of physical activity, comfortable at rest. Less than ordinary physical activity caused fatigue, palpitation, dyspnea or angina pain. Class IV: cardiac disease with inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or angina syndrome might be present even at rest. If any physical activity was undertaken, discomfort was increased. Participants with change from baseline were classified as improved (shifted from higher to lower class), unchanged (no change in class) or worsened (shifted from lower to higher class).
Time frame: Baseline, Month 12
Number of Participants With Change From Baseline in New York Heart Association (NYHA) Classification at Month 60
NYHA classified participants in 4 classes: Class I: cardiac disease without limitations of physical activity. Ordinary physical activity caused no undue fatigue, palpitation, dyspnea or angina pain. Class II: cardiac disease with slight limitation of physical activity, comfortable at rest. Ordinary physical activity resulted in fatigue, palpitation, dyspnea or angina pain. Class III: cardiac disease with marked limitation of physical activity, comfortable at rest. Less than ordinary physical activity caused fatigue, palpitation, dyspnea or angina pain. Class IV: cardiac disease with inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or angina syndrome might be present even at rest. If any physical activity was undertaken, discomfort was increased. Participants with change from baseline were classified as improved (shifted from higher to lower class), unchanged (no change in class) or worsened (shifted from lower to higher class).
Time frame: Baseline, Month 60
Change From Baseline in Total Distance Walked During 6 Minute Walk Test (6MWT) at Month 12
6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. In this outcome measure, the total distance that a participant could walk in 6 minutes was evaluated.
Time frame: Baseline, Month 12
Change From Baseline in Total Distance Walked During 6 Minute Walk Test (6MWT) at Month 60
6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. In this outcome measure, the total distance that a participant could walk in 6 minutes was evaluated.
Time frame: Baseline, Month 60
Number of Participants Categorized Based on Total Distance Walked During 6 Minute Walk Test (6MWT) at Month 12
6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. In this outcome measure, participants were categorized based on the total distance walked as Level 1 = total distance walked less than (\<) 300 meter; Level 2 = total distance walked between 300 to 374.9 meter; Level 3 = total distance walked between 375 to 449.9 meter; Level 4 = total distance walked greater than or equal to (\>=) 450 meter.
Time frame: Month 12
Number of Participants Categorized Based on Total Distance Walked During 6 Minute Walk Test (6MWT) at Month 60
6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. In this outcome measure, participants were categorized based on the total distance walked as Level 1 = total distance walked \< 300 meter; Level 2 = total distance walked between 300 to 374.9 meter; Level 3 = total distance walked between 375 to 449.9 meter; Level 4 = total distance walked \>=450 meter.
Time frame: Month 60
Change From Baseline in Dyspnea and Fatigue Scores During 6 Minute Walk Test (6MWT) at Month 12
6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. Dyspnea: participants were asked to rate the difficulty of their breathing, pre-walk and post-walk at each visit, on a scale of range 0 (no breathlessness at all) to 10 (maximum breathlessness). Higher scores indicated more severity. Fatigue: participants were asked to rate the how tired they felt, pre-walk and post-walk at each visit, on a scale of range 0 (not at all) to 10 (maximal) Higher scores indicated more fatigue. At each visit, scores for pre-walk test, post-walk test and within visit difference (difference from post-walk to pre-walk) were evaluated. Change from baseline was calculated for each pre-walk test, post-walk test and within visit difference at Month 12.
Time frame: Baseline, Month 12
Change From Baseline in Dyspnea and Fatigue Scores During 6 Minute Walk Test (6MWT) at Month 60
6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. Dyspnea: participants were asked to rate the difficulty of their breathing, pre-walk and post-walk at each visit, on a scale of range 0 (no breathlessness at all) to 10 (maximum breathlessness). Higher scores indicated more severity. Fatigue: participants were asked to rate the how tired they felt, pre-walk and post-walk at each visit, on a scale of range 0 (not at all) to 10 (maximal) Higher scores indicated more fatigue. At each visit, scores for pre-walk test, post-walk test and within visit difference (difference from post-walk to pre-walk) were evaluated. Change from baseline was calculated for each pre-walk test, post-walk test and within visit difference at Month 60.
Time frame: Baseline, Month 60
Number of Participants Categorized on Basis of Change From Baseline in Total Distance Walked During 6 Minute Walk Test (6MWT) at Month 12
6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. In this outcome measure, participants on basis of change from baseline in total distance walked were categorized as worsened, unchanged or improved. If distance walked at a visit was greater than distance walked at baseline, then categorized as 'improved'. If distance walked at a visit was equal to distance walked at baseline, then categorized as 'unchanged'. If distance walked at a visit was less than distance walked at baseline, then categorized as 'worsened'.
Time frame: Baseline, Month 12
Number of Participants Categorized on Basis of Change From Baseline in Total Distance Walked During 6 Minute Walk Test (6MWT) at Month 60
6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. In this outcome measure, participants on basis of change from baseline in total distance walked were categorized as worsened, unchanged or improved. If distance walked at a visit was greater than distance walked at baseline, then categorized as 'improved'. If distance walked at a visit was equal to distance walked at baseline, then categorized as 'unchanged'. If distance walked at a visit was less than distance walked at baseline, then categorized as 'worsened'.
Time frame: Baseline, Month 60
Change From Baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) Summary Score at Month 12
KCCQ is a 23-item participant-completed questionnaire that assesses health status and health-related quality of life in participants with heart failure. Eight domain scores were calculated for the KCCQ: physical limitation, social limitation, quality of life, self-efficacy, symptom stability, symptom frequency, symptom burden, and total symptoms (calculated as the mean of symptom frequency and symptom burden scores). Two summary scores were calculated: clinical summary (calculated as mean of physical limitation and total symptom scores) and overall summary (calculated as mean of physical limitation, social limitation, total symptoms, and quality of life scores). Each domain and both summary scores were scaled to range from 0 (worse health status) to 100 (best health status); higher scores represented better health status.
Time frame: Baseline, Month 12
Change From Baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) Summary Score at Month 60
KCCQ is a 23-item participant-completed questionnaire that assesses health status and health-related quality of life in participants with heart failure. Eight domain scores were calculated for the KCCQ: physical limitation, social limitation, quality of life, self-efficacy, symptom stability, symptom frequency, symptom burden, and total symptoms (calculated as the mean of symptom frequency and symptom burden scores). Two summary scores were calculated: clinical summary (calculated as mean of physical limitation and total symptom scores) and overall summary (calculated as mean of physical limitation, social limitation, total symptoms, and quality of life scores). Each domain and both summary scores were scaled to range from 0 (worse health status) to 100 (best health status); higher scores represented better health status.
Time frame: Baseline, Month 60
Change From Baseline in Troponin I and Troponin T Serum Levels at Month 12
Troponin I and troponin T are the cardiac markers. Troponin I and troponin T are part of the troponin complex, where troponin I is bound to actin in thin myofilaments and troponin T is bound to tropomyosin. Higher level of these markers is indicative of heart damage.
Time frame: Baseline, Month 12
Change From Baseline in Troponin I and Troponin T Serum Levels at Month 60
Troponin I and troponin T are the cardiac markers. Troponin I and troponin T are part of the troponin complex, where troponin I is bound to actin in thin myofilaments and troponin T is bound to tropomyosin. Higher level of these markers is indicative of heart damage.
Time frame: Baseline, Month 60
Change From Baseline in Amino-Terminal B-type Natriuretic Peptide (NT-proBNP) Serum Level at Month 12
NT-proBNP is biomarker of cardiac stress (myocardial necrosis and increased filling pressures/ left ventricular \[LV\] wall stress).
Time frame: Baseline, Month 12
Change From Baseline in Serum Levels of Amino-Terminal B-type Natriuretic Peptide (NT-proBNP) at Month 60
NT-proBNP is biomarker of cardiac stress (myocardial necrosis and increased filling pressures/ LV wall stress).
Time frame: Baseline, Month 60
Percentage of Participants With Categories of Patient Global Assessment (PGA) for Follow-up Visit: Months 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120, 126 and 132
Participants overall quality of life was measured by PGA. At each follow-up visit, participants were asked, "How do you feel today as compared to when we talked with you at your last clinic visit for this study?" and participants responded to any of the following: markedly improved, moderately improved, mildly improved, unchanged, mildly worsened, moderately worsened or markedly worsened.
Time frame: Month 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120, 126, 132
Number of Participants With Change From Baseline in New York Heart Association (NYHA) Classification at Months 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120, 126 and 132
NYHA classified participants in 4 classes: Class I: cardiac disease without limitations of physical activity. Ordinary physical activity caused no undue fatigue, palpitation, dyspnea or angina pain. Class II: cardiac disease with slight limitation of physical activity, comfortable at rest. Ordinary physical activity resulted in fatigue, palpitation, dyspnea or angina pain. Class III: cardiac disease with marked limitation of physical activity, comfortable at rest. Less than ordinary physical activity caused fatigue, palpitation, dyspnea or angina pain. Class IV: cardiac disease with inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or angina syndrome might be present even at rest. If any physical activity was undertaken, discomfort was increased. Participants with change from baseline were classified as improved (shifted from higher to lower class), unchanged (no change in class) or worsened (shifted from lower to higher class).
Time frame: Baseline, Month 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120, 126, 132
Change From Baseline in Total Distance Walked During 6 Minute Walk Test (6MWT) at Months 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120 and 132
6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. In this outcome measure, the total distance that a participant could walk in 6 minutes was evaluated.
Time frame: Baseline, Month 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120, 132
Number of Participants Categorized Based on Total Distance Walked During 6 Minute Walk Test (6MWT) at Baseline, Months 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120, 126 and 132
6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. In this outcome measure, participants were categorized based on the total distance walked as Level 1 = total distance walked \< 300 meter; Level 2 = total distance walked between 300 to 374.9 meter; Level 3 = total distance walked between 375 to 449.9 meter; Level 4 = total distance walked \>=450 meter.
Time frame: Baseline, Month 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120, 126, 132
Change From Baseline in Dyspnea and Fatigue Scores During 6 Minute Walk Test (6MWT) at Months 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120 and 132
6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. Dyspnea: participants were asked to rate the difficulty of their breathing, pre-walk and post-walk at each visit, on a scale of range 0 (no breathlessness at all) to 10 (maximum breathlessness). Higher scores indicated more severity. Fatigue: participants were asked to rate the how tired they felt, pre-walk and post-walk at each visit, on a scale of range 0 (not at all) to 10 (maximal) Higher scores indicated more fatigue. At each visit, scores for pre-walk test, post-walk test and within visit difference (difference from post-walk to pre-walk) were evaluated. Change from baseline was calculated for each pre-walk test, post-walk test and within visit difference at specified visits.
Time frame: Baseline, Month 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120, 132
Number of Participants Categorized on Basis of Change From Baseline in Total Distance Walked During 6 Minute Walk Test (6MWT) at Months 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120 and 132
6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. In this outcome measure, participants on basis of change from baseline in total distance walked were categorized as worsened, unchanged or improved. If distance walked at a visit was greater than distance walked at baseline, then categorized as 'improved'. If distance walked at a visit was equal to distance walked at baseline, then categorized as 'unchanged'. If distance walked at a visit was less than distance walked at baseline, then categorized as 'worsened'.
Time frame: Baseline, Month 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120, 132
Change From Baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) Summary Score at Months 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120, 126 and 132
KCCQ is a 23-item participant-completed questionnaire that assesses health status and health-related quality of life in participants with heart failure. Eight domain scores were calculated for the KCCQ: physical limitation, social limitation, quality of life, self-efficacy, symptom stability, symptom frequency, symptom burden, and total symptoms (calculated as the mean of symptom frequency and symptom burden scores). Two summary scores were calculated: clinical summary (calculated as mean of physical limitation and total symptom scores) and overall summary (calculated as mean of physical limitation, social limitation, total symptoms, and quality of life scores). Each domain and both summary scores were scaled to range from 0 (worse health status) to 100 (best health status); higher scores represented better health status.
Time frame: Baseline, Month 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120, 126, 132
Number of Participants With Abnormalities in Echocardiography
Echocardiography abnormalities included: absent respiratory variation of inferior vena cava, any valve thickening, aortic valve thickening, decreased respiratory variation of inferior vena cava, dilated inferior vena cava, E deceleration time less than or equal to (\<=) 150 millisecond, E wave/A Wave (E/A) ratio \>=2, ejection fraction \< 50%, isovolumic relaxation time (IVRT) \<=70 millisecond, left ventricular posterior wall thickness \>=13 millimeter (mm), left ventricular septal thickness \>= 13 mm, mitral valve thickening, pericardial effusion, pulmonary valve thickening, right ventricular thickness \>=7 mm, tricuspid valve thickening, ratio between early mitral inflow velocity and mitral annular early diastolic velocity (e/e') Lateral greater than (\>) 15, e/e' Septal \>15.
Time frame: Post-Month 12 up to Month 132 (approximately 10 years) of Study FX1B-303
Change From Baseline in Troponin I and Troponin T Serum Levels at Months 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120 and 126
Troponin I and troponin T are the cardiac markers. Troponin I and troponin T are part of the troponin complex, where troponin I is bound to actin in thin myofilaments and troponin T is bound to tropomyosin. Higher level of these markers is indicative of heart damage.
Time frame: Baseline, Month 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120 and 126
Change From Baseline in Amino-Terminal B-type Natriuretic Peptide (NT-proBNP) Serum Level at Months 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120 and 126
NT-proBNP was biomarker of cardiac stress (myocardial necrosis and increased filling pressures/ LV wall stress).
Time frame: Baseline, Month 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120, 126
Number of Participants With All-cause Hospitalization and Cardiac-related Hospitalization Events
All cause hospitalization was defined as any serious adverse event, which resulted in hospitalization. Cardiac-related hospitalization was any hospitalization meeting the following criteria: cardiac disorders or AE preferred term as chest discomfort, chest pain, death, cerebrovascular accident, embolic stroke, disease progression.
Time frame: Post-Month 12 up to Month 132 (approximately 10 years) of Study FX1B-303
Time to All-cause Mortality and Cardiac-Related Mortality
Time to death for all participants with a death date in Clinical Database, or censored at the last dose date + 28 days for those participants who were alive at the end of the study is reported.
Time frame: Post-Month 12 up to Month 132 (approximately 10 years) of Study FX1B-303
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both serious and all non-serious adverse events.
Time frame: Post-Month 12 up to Month 132 (approximately 10 years) of Study FX1B-303
Number of Participants With Treatment-Related Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both serious and all non-serious adverse events. Relatedness to study drug was assessed by the investigator as (Yes/No).
Time frame: Post-Month 12 up to Month 132 (approximately 10 years) of Study FX1B-303
Number of Participants With Clinically Significant Physical Examination Findings
Physical examination included examination of general appearance, endocrine, head and neck, cardiovascular, eyes, abdomen, ears, skin, nose, musculoskeletal, throat, neurological, respiratory, immunologic/allergies, genitourinary, hematologic/lymphatic. Clinical significance of any physical examination finding was judged by investigator.
Time frame: Post-Month 12 up to Month 132 (approximately 10 years) of Study FX1B-303
Number of Participants With Any Concomitant Medications
Number of participants who used medication other than study drug were reported.
Time frame: Post-Month 12 up to Month 132 (approximately 10 years) of Study FX1B-303
Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings
ECG parameters included PR interval (millisecond), RR interval (millisecond), QRS interval (millisecond), QT and QTc interval (millisecond) and heart rate (beats per minute). Clinical significance of any ECG finding was judged by investigator.
Time frame: Post-Month 12 up to Month 132 (approximately 10 years) of Study FX1B-303
Number of Participants With Laboratory Abnormalities
Laboratory parameters included hematology and biochemistry: alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen, gamma glutamyl transferase (GGT), creatinine, total bilirubin, international normalized ratio (INR), troponin I, troponin T, prothrombin time, sodium, globulin potassium, chloride, bicarbonate, cholesterol, calcium, uric acid, inorganic phosphorous, thyroid-stimulating hormone, glucose, total thyroxine (T4), free T4, total proteins, prealbumin (transthyretin), albumin, hemoglobin, platelets, hematocrit, white blood cell count, red blood cell count, neutrophils, packed cell volume, lymphocytes, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, eosinophils, mean corpuscular hemoglobin concentration, basophils, retinol-binding protein, Urinalysis: bilirubin, pH, blood (free Hb), protein, nitrite, glucose, urobilinogen, ketones, specific gravity.
Time frame: Post-Month 12 up to Month 132 (approximately 10 years) of Study FX1B-303
Participants with transthyretin amyloid cardiomyopathy (TTR-CM/ATTR-CM), who had not undergone liver or heart transplantation and who had completed previous study Fx1B-201 (NCT00694161) were eligible to enter this current study Fx1B-303 (NCT00935012).
| Milestone | Tafamidis 20 mg |
|---|---|
| Started | 31 |
| Completed | 2 |
| Not completed | 29 |
| Withdrew: Death | 19 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Other | 5 |
| Withdrew: Adverse event | 2 |
Participants overall quality of life was measured by PGA. At follow-up visit, participants were asked, "How do you feel today as compared to when we talked with you at your last clinic visit for this study?" and participants responded to any of the following: markedly improved, moderately improved, mildly improved, unchanged, mildly worsened, moderately worsened or markedly worsened.
| percentage of participants | Tafamidis 20 mg |
|---|---|
| Markedly Improved | 0 (0.0 to 11.2) |
| Moderately Improved | 16.1 (5.5 to 33.7) |
| Mildly Improved | 9.7 (2.0 to 25.8) |
| Unchanged | 51.6 (33.1 to 69.8) |
| Mildly Worsened | 12.9 (3.6 to 29.8) |
| Moderately Worsened | 9.7 (2.0 to 25.8) |
| Markedly Worsened | 0 (0.0 to 11.2) |
Participants overall quality of life was measured by PGA. At follow-up visit, participants were asked, "How do you feel today as compared to when we talked with you at your last clinic visit for this study?" and participants responded to any of the following: markedly improved, moderately improved, mildly improved, unchanged, mildly worsened, moderately worsened or markedly worsened.
| percentage of participants | Tafamidis 20 mg |
|---|---|
| Markedly Improved | 0 (0.0 to 26.5) |
| Moderately Improved | 8.3 (0.2 to 38.5) |
| Mildly Improved | 8.3 (0.2 to 38.5) |
| Unchanged | 50.0 (21.1 to 78.9) |
| Mildly Worsened | 16.7 (2.1 to 48.4) |
| Moderately Worsened | 16.7 (2.1 to 48.4) |
| Markedly Worsened | 0 (0.0 to 26.5) |
NYHA classified participants in 4 classes. Class I included participants with cardiac disease without limitations of physical activity. Ordinary physical activity did not cause undue fatigue, palpitation, dyspnea, or anginal pain. Class II included participants with cardiac disease with slight limitation of physical activity. They were comfortable at rest. Ordinary physical activity resulted in fatigue, palpitation, dyspnea, or anginal pain. Class III included participants with cardiac disease with marked limitation of physical activity. They were comfortable at rest. Less than ordinary physical activity caused fatigue, palpitation, dyspnea, or anginal pain. Class IV included participants with cardiac disease with the inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome might be present even at rest. If any physical activity was undertaken, discomfort was increased.
| Participants | Tafamidis 20 mg |
|---|---|
| CLASS I | 4 |
| CLASS II | 26 |
| CLASS III | 1 |
| CLASS IV | 0 |
NYHA classified participants in 4 classes: Class I: cardiac disease without limitations of physical activity. Ordinary physical activity caused no undue fatigue, palpitation, dyspnea or angina pain. Class II: cardiac disease with slight limitation of physical activity, comfortable at rest. Ordinary physical activity resulted in fatigue, palpitation, dyspnea or angina pain. Class III: cardiac disease with marked limitation of physical activity, comfortable at rest. Less than ordinary physical activity caused fatigue, palpitation, dyspnea or angina pain. Class IV: cardiac disease with inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or angina syndrome might be present even at rest. If any physical activity was undertaken, discomfort was increased. Participants with change from baseline were classified as improved (shifted from higher to lower class), unchanged (no change in class) or worsened (shifted from lower to higher class).
| Participants | Tafamidis 20 mg |
|---|---|
| Worsened | 7 |
| Unchanged | 20 |
| Improved | 4 |
NYHA classified participants in 4 classes: Class I: cardiac disease without limitations of physical activity. Ordinary physical activity caused no undue fatigue, palpitation, dyspnea or angina pain. Class II: cardiac disease with slight limitation of physical activity, comfortable at rest. Ordinary physical activity resulted in fatigue, palpitation, dyspnea or angina pain. Class III: cardiac disease with marked limitation of physical activity, comfortable at rest. Less than ordinary physical activity caused fatigue, palpitation, dyspnea or angina pain. Class IV: cardiac disease with inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or angina syndrome might be present even at rest. If any physical activity was undertaken, discomfort was increased. Participants with change from baseline were classified as improved (shifted from higher to lower class), unchanged (no change in class) or worsened (shifted from lower to higher class).
| Participants | Tafamidis 20 mg |
|---|---|
| Worsened | 8 |
| Unchanged | 3 |
| Improved | 1 |
6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. In this outcome measure, the total distance that a participant could walk in 6 minutes was evaluated.
| meters | Tafamidis 20 mg |
|---|---|
| Baseline | 363.7 ± 130.80 |
| Change at Month 12 | -11.2 ± 76.39 |
6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. In this outcome measure, the total distance that a participant could walk in 6 minutes was evaluated.
| meters | Tafamidis 20 mg |
|---|---|
| Change From Baseline in Total Distance Walked During 6 Minute Walk Test (6MWT) at Month 60 | -121.4 ± 145.82 |
6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. In this outcome measure, participants were categorized based on the total distance walked as Level 1 = total distance walked less than (\<) 300 meter; Level 2 = total distance walked between 300 to 374.9 meter; Level 3 = total distance walked between 375 to 449.9 meter; Level 4 = total distance walked greater than or equal to (\>=) 450 meter.
| Participants | Tafamidis 20 mg |
|---|---|
| Level 1 | 8 |
| Level 2 | 7 |
| Level 3 | 7 |
| Level 4 | 6 |
6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. In this outcome measure, participants were categorized based on the total distance walked as Level 1 = total distance walked \< 300 meter; Level 2 = total distance walked between 300 to 374.9 meter; Level 3 = total distance walked between 375 to 449.9 meter; Level 4 = total distance walked \>=450 meter.
| Participants | Tafamidis 20 mg |
|---|---|
| Level 1 | 4 |
| Level 2 | 3 |
| Level 3 | 0 |
| Level 4 | 1 |
6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. Dyspnea: participants were asked to rate the difficulty of their breathing, pre-walk and post-walk at each visit, on a scale of range 0 (no breathlessness at all) to 10 (maximum breathlessness). Higher scores indicated more severity. Fatigue: participants were asked to rate the how tired they felt, pre-walk and post-walk at each visit, on a scale of range 0 (not at all) to 10 (maximal) Higher scores indicated more fatigue. At each visit, scores for pre-walk test, post-walk test and within visit difference (difference from post-walk to pre-walk) were evaluated. Change from baseline was calculated for each pre-walk test, post-walk test and within visit difference at Month 12.
| units on a scale | Tafamidis 20 mg |
|---|---|
| Dyspnea: Baseline, Pre walk | 0.6 ± 0.72 |
| Dyspnea: Baseline, Post walk | 2.5 ± 1.94 |
| Dyspnea: Baseline, Within Visit Difference | 1.9 ± 1.94 |
| Dyspnea: Change at Month 12, Pre walk | 0.6 ± 1.61 |
| Dyspnea: Change at Month 12, Post walk | 1.2 ± 1.60 |
| Dyspnea:Change at Month 12,Within Visit Difference | 0.6 ± 1.70 |
| Fatigue: Baseline, Pre-walk | 0.9 ± 1.27 |
| Fatigue: Baseline, Post-walk | 2.4 ± 2.06 |
| Fatigue: Baseline, Within Visit Difference | 1.4 ± 2.51 |
| Fatigue: Change at Month 12, Pre Walk | 0.5 ± 2.20 |
| Fatigue: Change at Month 12, Post-Walk | 0.9 ± 1.98 |
| Fatigue:Change at Month 12,Within Visit Difference | 0.4 ± 2.20 |
6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. Dyspnea: participants were asked to rate the difficulty of their breathing, pre-walk and post-walk at each visit, on a scale of range 0 (no breathlessness at all) to 10 (maximum breathlessness). Higher scores indicated more severity. Fatigue: participants were asked to rate the how tired they felt, pre-walk and post-walk at each visit, on a scale of range 0 (not at all) to 10 (maximal) Higher scores indicated more fatigue. At each visit, scores for pre-walk test, post-walk test and within visit difference (difference from post-walk to pre-walk) were evaluated. Change from baseline was calculated for each pre-walk test, post-walk test and within visit difference at Month 60.
| units on a scale | Tafamidis 20 mg |
|---|---|
| Dyspnea: Change at Month 60, Pre walk | 0.8 ± 1.41 |
| Dyspnea: Change at Month 60, Post walk | 0.8 ± 1.60 |
| Dyspnea:Change at Month 60,Within Visit Difference | 0.1 ± 1.94 |
| Fatigue: Change at Month 60, Pre walk | 0.1 ± 0.35 |
| Fatigue: Change at Month 60, Post walk | 0.4 ± 1.51 |
| Fatigue:Change at Month 60,Within Visit Difference | 0.3 ± 1.49 |
6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. In this outcome measure, participants on basis of change from baseline in total distance walked were categorized as worsened, unchanged or improved. If distance walked at a visit was greater than distance walked at baseline, then categorized as 'improved'. If distance walked at a visit was equal to distance walked at baseline, then categorized as 'unchanged'. If distance walked at a visit was less than distance walked at baseline, then categorized as 'worsened'.
| Participants | Tafamidis 20 mg |
|---|---|
| Worsened | 7 |
| Unchanged | 16 |
| Improved | 5 |
6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. In this outcome measure, participants on basis of change from baseline in total distance walked were categorized as worsened, unchanged or improved. If distance walked at a visit was greater than distance walked at baseline, then categorized as 'improved'. If distance walked at a visit was equal to distance walked at baseline, then categorized as 'unchanged'. If distance walked at a visit was less than distance walked at baseline, then categorized as 'worsened'.
| Participants | Tafamidis 20 mg |
|---|---|
| Worsened | 5 |
| Unchanged | 3 |
| Improved | 0 |
KCCQ is a 23-item participant-completed questionnaire that assesses health status and health-related quality of life in participants with heart failure. Eight domain scores were calculated for the KCCQ: physical limitation, social limitation, quality of life, self-efficacy, symptom stability, symptom frequency, symptom burden, and total symptoms (calculated as the mean of symptom frequency and symptom burden scores). Two summary scores were calculated: clinical summary (calculated as mean of physical limitation and total symptom scores) and overall summary (calculated as mean of physical limitation, social limitation, total symptoms, and quality of life scores). Each domain and both summary scores were scaled to range from 0 (worse health status) to 100 (best health status); higher scores represented better health status.
| units on a scale | Tafamidis 20 mg |
|---|---|
| Overall Summary Score: Baseline | 72.21 ± 18.974 |
| Overall Summary Score: Change at Month 12 | -4.54 ± 12.724 |
| Clinical Summary Score: Baseline | 74.79 ± 19.296 |
| Clinical Summary Score: Change at Month 12 | -5.60 ± 13.792 |
KCCQ is a 23-item participant-completed questionnaire that assesses health status and health-related quality of life in participants with heart failure. Eight domain scores were calculated for the KCCQ: physical limitation, social limitation, quality of life, self-efficacy, symptom stability, symptom frequency, symptom burden, and total symptoms (calculated as the mean of symptom frequency and symptom burden scores). Two summary scores were calculated: clinical summary (calculated as mean of physical limitation and total symptom scores) and overall summary (calculated as mean of physical limitation, social limitation, total symptoms, and quality of life scores). Each domain and both summary scores were scaled to range from 0 (worse health status) to 100 (best health status); higher scores represented better health status.
| units on a scale | Tafamidis 20 mg |
|---|---|
| Overall Summary Score: Change at Month 60 | -12.93 ± 29.306 |
| Clinical Summary Score: Change at Month 60 | -18.12 ± 29.432 |
Troponin I and troponin T are the cardiac markers. Troponin I and troponin T are part of the troponin complex, where troponin I is bound to actin in thin myofilaments and troponin T is bound to tropomyosin. Higher level of these markers is indicative of heart damage.
| nanogram per milliliter | Tafamidis 20 mg |
|---|---|
| Troponin I: Baseline | 0.132 ± 0.0627 |
| Troponin I: Change at Month 12 | 0.016 ± 0.0652 |
| Troponin T: Baseline | 0.0448 ± 0.03402 |
| Troponin T: Change at Month 12 | 0.0110 ± 0.02239 |
Troponin I and troponin T are the cardiac markers. Troponin I and troponin T are part of the troponin complex, where troponin I is bound to actin in thin myofilaments and troponin T is bound to tropomyosin. Higher level of these markers is indicative of heart damage.
| nanogram per milliliter | Tafamidis 20 mg |
|---|---|
| Troponin T: Change at Month 60 | 0.026 ± 0.0937 |
| Troponin I: Change at Month 60 | 0.0810 ± 0.17779 |
NT-proBNP is biomarker of cardiac stress (myocardial necrosis and increased filling pressures/ left ventricular \[LV\] wall stress).
| nanogram per milliliter | Tafamidis 20 mg |
|---|---|
| Baseline | 4526.1 ± 3814.21 |
| Change at Month 12 | 818.3 ± 3133.86 |
NT-proBNP is biomarker of cardiac stress (myocardial necrosis and increased filling pressures/ LV wall stress).
| nanogram per milliliter | Tafamidis 20 mg |
|---|---|
| Change From Baseline in Serum Levels of Amino-Terminal B-type Natriuretic Peptide (NT-proBNP) at Month 60 | 5127.6 ± 10598.94 |
Participants overall quality of life was measured by PGA. At each follow-up visit, participants were asked, "How do you feel today as compared to when we talked with you at your last clinic visit for this study?" and participants responded to any of the following: markedly improved, moderately improved, mildly improved, unchanged, mildly worsened, moderately worsened or markedly worsened.
| percentage of participants | Tafamidis 20 mg |
|---|---|
| Month 6: Markedly Improved | 9.7 (2.0 to 25.8) |
| Month 6: Moderately Improved | 3.2 (0.1 to 16.7) |
| Month 6: Mildly Improved | 9.7 (2.0 to 25.8) |
| Month 6: Unchanged | 51.6 (33.1 to 69.8) |
| Month 6: Mildly Worsened | 25.8 (11.9 to 44.6) |
| Month 6: Moderately Worsened | 0 (0.0 to 11.2) |
| Month 6: Markedly Worsened | 0 (0.0 to 11.2) |
| Month 18: Markedly Improved | 7.1 (0.9 to 23.5) |
| Month 18: Moderately Improved | 10.7 (2.3 to 28.2) |
| Month 18: Mildly Improved | 17.9 (6.1 to 36.9) |
| Month 18: Unchanged | 25.0 (10.7 to 44.9) |
| Month 18: Mildly Worsened | 17.9 (6.1 to 36.9) |
| Month 18: Moderately Worsened | 10.7 (2.3 to 28.2) |
| Month 18: Markedly Worsened | 10.7 (2.3 to 28.2) |
| Month 24: Markedly Improved | 9.1 (1.1 to 29.2) |
| Month 24: Moderately Improved | 18.2 (5.2 to 40.3) |
| Month 24: Mildly Improved | 13.6 (2.9 to 34.9) |
| Month 24: Unchanged | 27.3 (10.7 to 50.2) |
| Month 24: Mildly Worsened | 22.7 (7.8 to 45.4) |
| Month 24: Moderately Worsened | 4.5 (0.1 to 22.8) |
| Month 24: Markedly Worsened | 4.5 (0.1 to 22.8) |
| Month 30: Markedly Improved | 0 (0.0 to 16.8) |
| Month 30: Moderately Improved | 10.0 (1.2 to 31.7) |
| Month 30: Mildly Improved | 5.0 (0.1 to 24.9) |
| Month 30: Unchanged | 40.0 (19.1 to 63.9) |
| Month 30: Mildly Worsened | 25.0 (8.7 to 49.1) |
| Month 30: Moderately Worsened | 20.0 (5.7 to 43.7) |
| Month 30: Markedly Worsened | 0 (0.0 to 16.8) |
| Month 36: Markedly Improved | 0 (0.0 to 17.6) |
| Month 36: Moderately Improved | 0 (0.0 to 17.6) |
| Month 36: Mildly Improved | 5.3 (0.1 to 26.0) |
| Month 36: Unchanged | 47.4 (24.4 to 71.1) |
| Month 36: Mildly Worsened | 26.3 (9.1 to 51.2) |
| Month 36: Moderately Worsened | 21.1 (6.1 to 45.6) |
| Month 36: Markedly Worsened | 0 (0.0 to 17.6) |
| Month 42: Markedly Improved | 0 (0.0 to 19.5) |
| Month 42: Moderately Improved | 0 (0.0 to 19.5) |
| Month 42: Mildly Improved | 0 (0.0 to 19.5) |
| Month 42: Unchanged | 29.4 (10.3 to 56.0) |
| Month 42: Mildly Worsened | 35.3 (14.2 to 61.7) |
| Month 42: Moderately Worsened | 11.8 (1.5 to 36.4) |
| Month 42: Markedly Worsened | 23.5 (6.8 to 49.9) |
| Month 48: Markedly Improved | 0 (0.0 to 24.7) |
| Month 48: Moderately Improved | 0 (0.0 to 24.7) |
| Month 48: Mildly Improved | 23.1 (5.0 to 53.8) |
| Month 48: Unchanged | 53.8 (25.1 to 80.8) |
| Month 48: Mildly Worsened | 15.4 (1.9 to 45.4) |
| Month 48: Moderately Worsened | 7.7 (0.2 to 36.0) |
| Month 48: Markedly Worsened | 0 (0.0 to 24.7) |
| Month 54: Markedly Improved | 0 (0.0 to 24.7) |
| Month 54: Moderately Improved | 7.7 (0.2 to 36.0) |
| Month 54: Mildly Improved | 0 (0.0 to 24.7) |
| Month 54: Unchanged | 61.5 (31.6 to 86.1) |
| Month 54: Mildly Worsened | 23.1 (5.0 to 53.8) |
| Month 54: Moderately Worsened | 7.7 (0.2 to 36.0) |
| Month 54: Markedly Worsened | 0 (0.0 to 24.7) |
| Month 66: Markedly Improved | 16.7 (0.4 to 64.1) |
| Month 66: Moderately Improved | 0 (0.0 to 45.9) |
| Month 66: Mildly Improved | 0 (0.0 to 45.9) |
| Month 66: Unchanged | 50.0 (11.8 to 88.2) |
| Month 66: Mildly Worsened | 0 (0.0 to 45.9) |
| Month 66: Moderately Worsened | 33.3 (4.3 to 77.7) |
| Month 66: Markedly Worsened | 0 (0.0 to 45.9) |
| Month 72: Markedly Improved | 0 (0.0 to 41.0) |
| Month 72: Moderately Improved | 0 (0.0 to 41.0) |
| Month 72: Mildly Improved | 0 (0.0 to 41.0) |
| Month 72: Unchanged | 71.4 (29.0 to 96.3) |
| Month 72: Mildly Worsened | 28.6 (3.7 to 71.0) |
| Month 72: Moderately Worsened | 0 (0.0 to 41.0) |
| Month 72: Markedly Worsened | 0 (0.0 to 41.0) |
| Month 78: Markedly Improved | 14.3 (0.4 to 57.9) |
| Month 78: Moderately Improved | 0 (0.0 to 41.0) |
| Month 78: Mildly Improved | 0 (0.0 to 41.0) |
| Month 78: Unchanged | 28.6 (3.7 to 71.0) |
| Month 78: Mildly Worsened | 28.6 (3.7 to 71.0) |
| Month 78: Moderately Worsened | 28.6 (3.7 to 71.0) |
| Month 78: Markedly Worsened | 0 (0.0 to 41.0) |
| Month 84: Markedly Improved | 16.7 (0.4 to 64.1) |
| Month 84: Moderately Improved | 0 (0.0 to 45.9) |
| Month 84: Mildly Improved | 0 (0.0 to 45.9) |
| Month 84: Unchanged | 33.3 (4.3 to 77.7) |
| Month 84: Mildly Worsened | 16.7 (0.4 to 64.1) |
| Month 84: Moderately Worsened | 16.7 (0.4 to 64.1) |
| Month 84: Markedly Worsened | 16.7 (0.4 to 64.1) |
| Month 90: Markedly Improved | 0 (0.0 to 41.0) |
| Month 90: Moderately Improved | 0 (0.0 to 41.0) |
| Month 90: Mildly Improved | 42.9 (9.9 to 81.6) |
| Month 90: Unchanged | 28.6 (3.7 to 71.0) |
| Month 90: Mildly Worsened | 28.6 (3.7 to 71.0) |
| Month 90: Moderately Worsened | 0 (0.0 to 41.0) |
| Month 90: Markedly Worsened | 0 (0.0 to 41.0) |
| Month 96: Markedly Improved | 0 (0.0 to 60.2) |
| Month 96: Moderately Improved | 0 (0.0 to 60.2) |
| Month 96: Mildly Improved | 0 (0.0 to 60.2) |
| Month 96: Unchanged | 25.0 (0.6 to 80.6) |
| Month 96: Mildly Worsened | 50.0 (6.8 to 93.2) |
| Month 96: Moderately Worsened | 25.0 (0.6 to 80.6) |
| Month 96: Markedly Worsened | 0 (0.0 to 60.2) |
| Month 102: Markedly Improved | 0 (0.0 to 60.2) |
| Month 102: Moderately Improved | 0 (0.0 to 60.2) |
| Month 102: Mildly Improved | 0 (0.0 to 60.2) |
| Month 102: Unchanged | 75.0 (19.4 to 99.4) |
| Month 102: Mildly Worsened | 0 (0.0 to 60.2) |
| Month 102: Moderately Worsened | 0 (0.0 to 60.2) |
| Month 102: Markedly Worsened | 25.0 (0.6 to 80.6) |
| Month 108: Markedly Improved | 40.0 (5.3 to 85.3) |
| Month 108: Moderately Improved | 0 (0.0 to 52.2) |
| Month 108: Mildly Improved | 20.0 (0.5 to 71.6) |
| Month 108: Unchanged | 40.0 (5.3 to 85.3) |
| Month 108: Mildly Worsened | 0 (0.0 to 52.2) |
| Month 108: Moderately Worsened | 0 (0.0 to 52.2) |
| Month 108: Markedly Worsened | 0 (0.0 to 52.2) |
| Month 114: Markedly Improved | 0 (0.0 to 60.2) |
| Month 114: Moderately Improved | 0 (0.0 to 60.2) |
| Month 114: Mildly Improved | 25.0 (0.6 to 80.6) |
| Month 114: Unchanged | 0 (0.0 to 60.2) |
| Month 114: Mildly Worsened | 75.0 (19.4 to 99.4) |
| Month 114: Moderately Worsened | 0 (0.0 to 60.2) |
| Month 114: Markedly Worsened | 0 (0.0 to 60.2) |
| Month 120: Markedly Improved | 0 (0.0 to 84.2) |
| Month 120: Moderately Improved | 0 (0.0 to 84.2) |
| Month 120: Mildly Improved | 50.0 (1.3 to 98.7) |
| Month 120: Unchanged | 50.0 (1.3 to 98.7) |
| Month 120: Mildly Worsened | 0 (0.0 to 84.2) |
| Month 120: Moderately Worsened | 0 (0.0 to 84.2) |
| Month 120: Markedly Worsened | 0 (0.0 to 84.2) |
| Month 126: Markedly Improved | 0 (0.0 to 84.2) |
| Month 126: Moderately Improved | 0 (0.0 to 84.2) |
| Month 126: Mildly Improved | 0 (0.0 to 84.2) |
| Month 126: Unchanged | 0 (0.0 to 84.2) |
| Month 126: Mildly Worsened | 100.0 (15.8 to 100.0) |
| Month 126: Moderately Worsened | 0 (0.0 to 84.2) |
| Month 126: Markedly Worsened | 0 (0.0 to 84.2) |
| Month 132: Markedly Improved | 0 (0.0 to 97.5) |
| Month 132: Moderately Improved | 0 (0.0 to 97.5) |
| Month 132: Mildly Improved | 0 (0.0 to 97.5) |
| Month 132: Unchanged | 0 (0.0 to 97.5) |
| Month 132: Mildly Worsened | 100.0 (2.5 to 100.0) |
| Month 132: Moderately Worsened | 0 (0.0 to 97.5) |
| Month 132: Markedly Worsened | 0 (0.0 to 97.5) |
NYHA classified participants in 4 classes: Class I: cardiac disease without limitations of physical activity. Ordinary physical activity caused no undue fatigue, palpitation, dyspnea or angina pain. Class II: cardiac disease with slight limitation of physical activity, comfortable at rest. Ordinary physical activity resulted in fatigue, palpitation, dyspnea or angina pain. Class III: cardiac disease with marked limitation of physical activity, comfortable at rest. Less than ordinary physical activity caused fatigue, palpitation, dyspnea or angina pain. Class IV: cardiac disease with inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or angina syndrome might be present even at rest. If any physical activity was undertaken, discomfort was increased. Participants with change from baseline were classified as improved (shifted from higher to lower class), unchanged (no change in class) or worsened (shifted from lower to higher class).
| Participants | Tafamidis 20 mg |
|---|---|
| Month 6: Worsened | 5 |
| Month 6: Unchanged | 25 |
| Month 6: Improved | 1 |
| Month 18: Worsened | 7 |
| Month 18: Unchanged | 17 |
| Month 18: Improved | 3 |
| Month 24: Worsened | 7 |
| Month 24: Unchanged | 12 |
| Month 24: Improved | 3 |
| Month 30: Worsened | 4 |
| Month 30: Unchanged | 14 |
| Month 30: Improved | 2 |
| Month 36: Worsened | 6 |
| Month 36: Unchanged | 11 |
| Month 36: Improved | 2 |
| Month 42: Worsened | 10 |
| Month 42: Unchanged | 5 |
| Month 42: Improved | 2 |
| Month 48: Worsened | 6 |
| Month 48: Unchanged | 4 |
| Month 48: Improved | 2 |
| Month 54: Worsened | 6 |
| Month 54: Unchanged | 6 |
| Month 54: Improved | 0 |
| Month 66: Worsened | 5 |
| Month 66: Unchanged | 1 |
| Month 66: Improved | 0 |
| Month 72: Worsened | 2 |
| Month 72: Unchanged | 5 |
| Month 72: Improved | 0 |
| Month 78: Worsened | 3 |
| Month 78: Unchanged | 4 |
| Month 78: Improved | 0 |
| Month 84: Worsened | 3 |
| Month 84: Unchanged | 3 |
| Month 84: Improved | 0 |
| Month 90: Worsened | 3 |
| Month 90: Unchanged | 4 |
| Month 90: Improved | 0 |
| Month 96: Worsened | 3 |
| Month 96: Unchanged | 1 |
| Month 96: Improved | 1 |
| Month 102: Worsened | 2 |
| Month 102: Unchanged | 2 |
| Month 102: Improved | 1 |
| Month 108: Worsened | 2 |
| Month 108: Unchanged | 1 |
| Month 108: Improved | 2 |
| Month 114: Worsened | 2 |
| Month 114: Unchanged | 2 |
| Month 114: Improved | 0 |
| Month 120: Worsened | 3 |
| Month 120: Unchanged | 1 |
| Month 120: Improved | 0 |
| Month 126: Worsened | 1 |
| Month 126: Unchanged | 1 |
| Month 126: Improved | 0 |
| Month 132: Worsened | 1 |
| Month 132: Unchanged | 0 |
| Month 132: Improved | 0 |
6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. In this outcome measure, the total distance that a participant could walk in 6 minutes was evaluated.
| meters | Tafamidis 20 mg |
|---|---|
| Change at Month 6 | 2.9 ± 60.64 |
| Change at Month 18 | -21.6 ± 108.19 |
| Change at Month 24 | -15.7 ± 78.39 |
| Change at Month 30 | -44.5 ± 111.67 |
| Change at Month 36 | -63.5 ± 101.37 |
| Change at Month 42 | -95.2 ± 124.79 |
| Change at Month 48 | -110.9 ± 128.57 |
| Change at Month 54 | -127.8 ± 124.01 |
| Change at Month 66 | -63.2 ± 114.20 |
| Change at Month 72 | -139.5 ± 210.18 |
| Change at Month 78 | -94.3 ± 177.01 |
| Change at Month 84 | -100.3 ± 151.71 |
| Change at Month 90 | -97.6 ± 125.50 |
| Change at Month 96 | -118.9 ± 114.20 |
| Change at Month 102 | -82.3 ± 19.30 |
| Change at Month 108 | -141.9 ± 112.29 |
| Change at Month 114 | -166.9 ± 137.23 |
| Change at Month 120 | -184.5 ± 82.22 |
| Change at Month 132 | -289.6 |
6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. In this outcome measure, participants were categorized based on the total distance walked as Level 1 = total distance walked \< 300 meter; Level 2 = total distance walked between 300 to 374.9 meter; Level 3 = total distance walked between 375 to 449.9 meter; Level 4 = total distance walked \>=450 meter.
| Participants | Tafamidis 20 mg |
|---|---|
| Baseline: Level 1 | 8 |
| Baseline: Level 2 | 10 |
| Baseline: Level 3 | 7 |
| Baseline: Level 4 | 5 |
| Month 6: Level 1 | 7 |
| Month 6: Level 2 | 9 |
| Month 6: Level 3 | 9 |
| Month 6: Level 4 | 5 |
| Month 18:Level 1 | 5 |
| Month 18: Level 2 | 5 |
| Month 18: Level 3 | 8 |
| Month 18: Level 4 | 3 |
| Month 24: Level 1 | 3 |
| Month 24: Level 2 | 7 |
| Month 24: Level 3 | 4 |
| Month 24: Level 4 | 6 |
| Month 30: Level 1 | 5 |
| Month 30: Level 2 | 6 |
| Month 30: Level 3 | 6 |
| Month 30: Level 4 | 1 |
| Month 36: Level 1 | 5 |
| Month 36: Level 2 | 4 |
| Month 36: Level 3 | 6 |
| Month 36: Level 4 | 2 |
| Month 42: Level 1 | 9 |
| Month 42: Level 2 | 2 |
| Month 42: Level 3 | 4 |
| Month 42: Level 4 | 1 |
| Month 48: Level 1 | 5 |
| Month 48: Level 2 | 1 |
| Month 48: Level 3 | 5 |
| Month 48: Level 4 | 0 |
| Month 54: Level 1 | 7 |
| Month 54: Level 2 | 2 |
| Month 54: Level 3 | 1 |
| Month 54: Level 4 | 1 |
| Month 66: Level 1 | 2 |
| Month 66: Level 2 | 1 |
| Month 66: Level 3 | 1 |
| Month 66: Level 4 | 0 |
| Month 72: Level 1 | 2 |
| Month 72: Level 2 | 0 |
| Month 72: Level 3 | 1 |
| Month 72: Level 4 | 0 |
| Month 78: Level 1 | 2 |
| Month 78: Level 2 | 0 |
| Month 78: Level 3 | 1 |
| Month 78: Level 4 | 0 |
| Month 84: Level 1 | 2 |
| Month 84: Level 2 | 2 |
| Month 84: Level 3 | 0 |
| Month 84: Level 4 | 0 |
| Month 90: Level 1 | 3 |
| Month 90: Level 2 | 1 |
| Month 90: Level 3 | 2 |
| Month 90: Level 4 | 0 |
| Month 96: Level 1 | 3 |
| Month 96: Level 2 | 1 |
| Month 96: Level 3 | 0 |
| Month 96: Level 4 | 0 |
| Month 102: Level 1 | 0 |
| Month 102: Level 2 | 2 |
| Month 102: Level 3 | 1 |
| Month 102: Level 4 | 0 |
| Month 108: Level 1 | 3 |
| Month 108: Level 2 | 2 |
| Month 108: Level 3 | 0 |
| Month 108: Level 4 | 0 |
| Month 114: Level 1 | 3 |
| Month 114: Level 2 | 1 |
| Month 114: Level 3 | 0 |
| Month 114: Level 4 | 0 |
| Month 120: Level 1 | 1 |
| Month 120: Level 2 | 2 |
| Month 120: Level 3 | 0 |
| Month 120: Level 4 | 0 |
| Month 132: Level 1 | 1 |
| Month 132: Level 2 | 0 |
| Month 132: Level 3 | 0 |
| Month 132: Level 4 | 0 |
6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. Dyspnea: participants were asked to rate the difficulty of their breathing, pre-walk and post-walk at each visit, on a scale of range 0 (no breathlessness at all) to 10 (maximum breathlessness). Higher scores indicated more severity. Fatigue: participants were asked to rate the how tired they felt, pre-walk and post-walk at each visit, on a scale of range 0 (not at all) to 10 (maximal) Higher scores indicated more fatigue. At each visit, scores for pre-walk test, post-walk test and within visit difference (difference from post-walk to pre-walk) were evaluated. Change from baseline was calculated for each pre-walk test, post-walk test and within visit difference at specified visits.
| units on a scale | Tafamidis 20 mg |
|---|---|
| Dyspnea: Change at Month 6, Pre walk | 0.3 ± 1.32 |
| Dyspnea: Change at Month 6, Post walk | 0.9 ± 1.54 |
| Dyspnea: Change at Month 6,Within Visit Difference | 0.6 ± 1.56 |
| Dyspnea: Change at Month 18, Pre walk | 0.3 ± 1.11 |
| Dyspnea: Change at Month 18, Post walk | 0.8 ± 1.40 |
| Dyspnea:Change at Month 18,Within Visit Difference | 0.6 ± 1.93 |
| Dyspnea: Change at Month 24, Pre walk | 0.3 ± 0.75 |
| Dyspnea: Change at Month 24, Post walk | 1.5 ± 1.91 |
| Dyspnea:Change at Month 24,Within Visit Difference | 1.1 ± 2.02 |
| Dyspnea: Change at Month 30, Pre walk | 0.2 ± 0.47 |
| Dyspnea: Change at Month 30, Post walk | 1.2 ± 1.27 |
| Dyspnea:Change at Month 30,Within Visit Difference | 1.0 ± 1.36 |
| Dyspnea: Change at Month 36, Pre walk | 0.1 ± 1.36 |
| Dyspnea: Change at Month 36, Post walk | -0.2 ± 2.68 |
| Dyspnea:Change at Month 36,Within Visit Difference | -0.3 ± 1.97 |
| Dyspnea: Change at Month 42, Pre walk | 0.5 ± 0.90 |
| Dyspnea: Change at Month 42, Post walk | 1.0 ± 1.45 |
| Dyspnea:Change at Month 42,Within Visit Difference | 0.5 ± 1.53 |
| Dyspnea: Change at Month 48, Pre walk | 0.6 ± 1.17 |
| Dyspnea: Change at Month 48, Post walk | 1.3 ± 0.98 |
| Dyspnea:Change at Month 48,Within Visit Difference | 0.8 ± 1.64 |
| Dyspnea: Change at Month 54, Pre walk | 0.4 ± 1.56 |
| Dyspnea: Change at Month 54, Post walk | 1.0 ± 1.93 |
| Dyspnea:Change at Month 54,Within Visit Difference | 0.6 ± 1.91 |
| Dyspnea: Change at Month 66, Pre walk | 1.4 ± 1.11 |
| Dyspnea: Change at Month 66, Post walk | 1.5 ± 1.29 |
| Dyspnea:Change at Month 66,Within Visit Difference | 0.1 ± 1.18 |
| Dyspnea: Change at Month 72, Pre walk | 0.8 ± 1.44 |
| Dyspnea: Change at Month 72, Post walk | 0.7 ± 1.15 |
| Dyspnea:Change at Month 72,Within Visit Difference | -0.2 ± 0.29 |
| Dyspnea: Change at Month 78, Pre walk | 2.2 ± 2.02 |
| Dyspnea: Change at Month 78, Post walk | 0.7 ± 0.58 |
| Dyspnea:Change at Month 78,Within Visit Difference | -1.5 ± 1.50 |
| Dyspnea: Change at Month 84, Pre walk | -0.1 ± 0.85 |
| Dyspnea: Change at Month 84, Post walk | 0.5 ± 1.00 |
| Dyspnea:Change at Month 84,Within Visit Difference | 0.6 ± 1.70 |
| Dyspnea: Change at Month 90, Pre walk | 0.6 ± 0.66 |
| Dyspnea: Change at Month 90, Post walk | -0.8 ± 2.32 |
| Dyspnea:Change at Month 90,Within Visit Difference | -1.4 ± 2.20 |
| Dyspnea: Change at Month 96, Pre walk | 1.0 ± 1.41 |
| Dyspnea: Change at Month 96, Post walk | 1.3 ± 1.50 |
| Dyspnea:Change at Month 96,Within Visit Difference | 0.3 ± 2.36 |
| Dyspnea: Change at Month 102, Pre walk | -0.3 ± 0.58 |
| Dyspnea: Change at Month 102, Post walk | -1.3 ± 4.04 |
| Dyspnea:Change at Month102,Within Visit Difference | -1.0 ± 3.46 |
| Dyspnea: Change at Month 108, Pre walk | 1.7 ± 2.82 |
| Dyspnea: Change at Month 108, Post walk | 0.7 ± 4.97 |
| Dyspnea:Change at Month108,Within Visit Difference | -1.0 ± 2.81 |
| Dyspnea: Change at Month 114, Pre walk | 0.4 ± 1.80 |
| Dyspnea: Change at Month 114, Post walk | 0.1 ± 0.63 |
| Dyspnea:Change at Month114,Within Visit Difference | -0.3 ± 1.19 |
| Dyspnea: Change at Month 120, Pre walk | 0.3 ± 1.53 |
| Dyspnea: Change at Month 120, Post walk | -0.8 ± 1.04 |
| Dyspnea:Change at Month120,Within Visit Difference | -1.2 ± 2.47 |
| Dyspnea: Change at Month 132, Pre walk | -1.0 |
| Dyspnea: Change at Month 132, Post walk | -1.0 |
| Dyspnea:Change at Month132,Within Visit Difference | 0.0 |
| Fatigue: Change at Month 6, Pre walk | 0.2 ± 1.69 |
| Fatigue: Change at Month 6, Post walk | 0.7 ± 2.82 |
| Fatigue:Change at Month 6,Within Visit Difference | 0.4 ± 2.92 |
| Fatigue: Change at Month 18, Pre walk | 0.0 ± 2.13 |
| Fatigue: Change at Month 18, Post walk | 0.2 ± 1.40 |
| Fatigue:Change at Month 18,Within Visit Difference | 0.2 ± 2.51 |
| Fatigue: Change at Month 24, Pre walk | 0.1 ± 1.66 |
| Fatigue: Change at Month 24, Post walk | 1.0 ± 2.33 |
| Fatigue:Change at Month 24,Within Visit Difference | 0.9 ± 2.97 |
| Fatigue: Change at Month 30, Pre walk | -0.4 ± 1.58 |
| Fatigue: Change at Month 30, Post walk | 0.9 ± 1.65 |
| Fatigue:Change at Month 30,Within Visit Difference | 1.3 ± 2.23 |
| Fatigue: Change at Month 36, Pre walk | -0.2 ± 2.29 |
| Fatigue: Change at Month 36, Post walk | 0.8 ± 2.05 |
| Fatigue:Change at Month 36,Within Visit Difference | 1.0 ± 2.76 |
| Fatigue: Change at Month 42, Pre walk | 0.4 ± 1.76 |
| Fatigue: Change at Month 42, Post walk | 1.6 ± 1.86 |
| Fatigue:Change at Month 42,Within Visit Difference | 1.2 ± 2.86 |
| Fatigue: Change at Month 48, Pre walk | 0.6 ± 1.26 |
| Fatigue: Change at Month 48, Post walk | 1.5 ± 1.84 |
| Fatigue:Change at Month 48,Within Visit Difference | 0.9 ± 2.38 |
| Fatigue: Change at Month 54, Pre walk | 0.5 ± 1.57 |
| Fatigue: Change at Month 54, Post walk | 0.5 ± 1.90 |
| Fatigue:Change at Month 54,Within Visit Difference | -0.1 ± 1.97 |
| Fatigue: Change at Month 66, Pre walk | 0.3 ± 0.50 |
| Fatigue: Change at Month 66, Post walk | 0.5 ± 2.38 |
| Fatigue:Change at Month 66,Within Visit Difference | 0.3 ± 2.22 |
| Fatigue: Change at Month 72, Pre walk | 2.0 ± 1.73 |
| Fatigue: Change at Month 72, Post walk | 1.0 ± 1.73 |
| Fatigue:Change at Month 72,Within Visit Difference | -1.0 ± 0.00 |
| Fatigue: Change at Month 78, Pre walk | 2.0 ± 2.00 |
| Fatigue: Change at Month 78, Post walk | 1.0 ± 2.65 |
| Fatigue:Change at Month 78,Within Visit Difference | -1.0 ± 1.00 |
| Fatigue: Change at Month 84, Pre walk | 0.0 ± 0.82 |
| Fatigue: Change at Month 84, Post walk | 0.4 ± 1.11 |
| Fatigue:Change at Month 84,Within Visit Difference | 0.4 ± 1.49 |
| Fatigue: Change at Month 90, Pre walk | 1.3 ± 1.75 |
| Fatigue: Change at Month 90, Post walk | -0.3 ± 2.07 |
| Fatigue:Change at Month 90,Within Visit Difference | -1.7 ± 3.27 |
| Fatigue: Change at Month 96, Pre walk | 0.8 ± 1.50 |
| Fatigue: Change at Month 96, Post walk | 0.0 ± 0.82 |
| Fatigue:Change at Month 96,Within Visit Difference | -0.8 ± 1.71 |
| Fatigue: Change at Month 102, Pre walk | 1.0 ± 2.65 |
| Fatigue: Change at Month 102, Post walk | -0.7 ± 1.53 |
| Fatigue:Change at Month102,Within Visit Difference | -1.7 ± 1.15 |
| Fatigue: Change at Month 108, Pre walk | 1.8 ± 2.77 |
| Fatigue: Change at Month 108, Post walk | 0.9 ± 3.54 |
| Fatigue:Change at Month108,Within Visit Difference | -0.9 ± 1.14 |
| Fatigue: Change at Month 114, Pre walk | 1.0 ± 2.16 |
| Fatigue: Change at Month 114, Post walk | -0.1 ± 0.85 |
| Fatigue:Change at Month114,Within Visit Difference | -1.1 ± 1.44 |
| Fatigue: Change at Month 120, Pre walk | 0.0 ± 1.00 |
| Fatigue: Change at Month 120, Post walk | -1.2 ± 0.76 |
| Fatigue:Change at Month120,Within Visit Difference | -1.2 ± 1.76 |
| Fatigue: Change at Month 132, Pre walk | -1.0 |
| Fatigue: Change at Month 132, Post walk | -0.5 |
| Fatigue:Change at Month132,Within Visit Difference | 0.5 |
6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. In this outcome measure, participants on basis of change from baseline in total distance walked were categorized as worsened, unchanged or improved. If distance walked at a visit was greater than distance walked at baseline, then categorized as 'improved'. If distance walked at a visit was equal to distance walked at baseline, then categorized as 'unchanged'. If distance walked at a visit was less than distance walked at baseline, then categorized as 'worsened'.
| Participants | Tafamidis 20 mg |
|---|---|
| Month 6: Worsened | 5 |
| Month 6: Unchanged | 20 |
| Month 6: Improved | 5 |
| Month 18: Worsened | 9 |
| Month 18: Unchanged | 7 |
| Month 18: Improved | 5 |
| Month 24: Worsened | 6 |
| Month 24: Unchanged | 10 |
| Month 24: Improved | 4 |
| Month 30: Worsened | 9 |
| Month 30: Unchanged | 4 |
| Month 30: Improved | 5 |
| Month 36: Worsened | 8 |
| Month 36: Unchanged | 7 |
| Month 36: Improved | 2 |
| Month 42: Worsened | 9 |
| Month 42: Unchanged | 6 |
| Month 42: Improved | 1 |
| Month 48: Worsened | 7 |
| Month 48: Unchanged | 3 |
| Month 48: Improved | 1 |
| Month 54: Worsened | 7 |
| Month 54: Unchanged | 4 |
| Month 54: Improved | 0 |
| Month 66: Worsened | 3 |
| Month 66: Unchanged | 1 |
| Month 66: Improved | 0 |
| Month 72: Worsened | 2 |
| Month 72: Unchanged | 1 |
| Month 72: Improved | 0 |
| Month 78: Worsened | 2 |
| Month 78: Unchanged | 1 |
| Month 78: Improved | 0 |
| Month 84: Worsened | 3 |
| Month 84: Unchanged | 1 |
| Month 84: Improved | 0 |
| Month 90: Worsened | 4 |
| Month 90: Unchanged | 1 |
| Month 90: Improved | 1 |
| Month 96: Worsened | 3 |
| Month 96: Unchanged | 1 |
| Month 96: Improved | 0 |
| Month 102: Worsened | 2 |
| Month 102: Unchanged | 1 |
| Month 102: Improved | 0 |
| Month 108: Worsened | 4 |
| Month 108: Unchanged | 1 |
| Month 108: Improved | 0 |
| Month 114: Worsened | 3 |
| Month 114: Unchanged | 1 |
| Month 114: Improved | 0 |
| Month 120: Worsened | 3 |
| Month 120: Unchanged | 0 |
| Month 120: Improved | 0 |
| Month 132: Worsened | 1 |
| Month 132: Unchanged | 0 |
| Month 132: Improved | 0 |
KCCQ is a 23-item participant-completed questionnaire that assesses health status and health-related quality of life in participants with heart failure. Eight domain scores were calculated for the KCCQ: physical limitation, social limitation, quality of life, self-efficacy, symptom stability, symptom frequency, symptom burden, and total symptoms (calculated as the mean of symptom frequency and symptom burden scores). Two summary scores were calculated: clinical summary (calculated as mean of physical limitation and total symptom scores) and overall summary (calculated as mean of physical limitation, social limitation, total symptoms, and quality of life scores). Each domain and both summary scores were scaled to range from 0 (worse health status) to 100 (best health status); higher scores represented better health status.
| units on a scale | Tafamidis 20 mg |
|---|---|
| Overall Summary Score: Change at Month 6 | -2.12 ± 12.423 |
| Overall Summary Score: Change at Month 18 | -4.58 ± 18.926 |
| Overall Summary Score: Change at Month 24 | -2.94 ± 16.247 |
| Overall Summary Score: Change at Month 30 | -5.41 ± 17.695 |
| Overall Summary Score: Change at Month 36 | -6.86 ± 18.525 |
| Overall Summary Score: Change at Month 42 | -12.76 ± 23.646 |
| Overall Summary Score: Change at Month 48 | -13.22 ± 24.893 |
| Overall Summary Score: Change at Month 54 | -14.99 ± 23.688 |
| Overall Summary Score: Change at Month 66 | -1.77 ± 30.476 |
| Overall Summary Score: Change at Month 72 | 0.41 ± 23.317 |
| Overall Summary Score: Change at Month 78 | -3.60 ± 24.231 |
| Overall Summary Score: Change at Month 84 | -3.72 ± 32.770 |
| Overall Summary Score: Change at Month 90 | -0.28 ± 30.296 |
| Overall Summary Score: Change at Month 96 | -17.84 ± 47.842 |
| Overall Summary Score: Change at Month 102 | -12.63 ± 40.904 |
| Overall Summary Score: Change at Month 108 | -1.19 ± 35.375 |
| Overall Summary Score: Change at Month 114 | -2.99 ± 37.897 |
| Overall Summary Score: Change at Month 120 | -35.55 ± 9.023 |
| Overall Summary Score: Change at Month 126 | -39.32 ± 8.102 |
| Overall Summary Score: Change at Month 132 | -40.10 |
| Clinical Summary Score: Change at Month 6 | -3.00 ± 11.650 |
| Clinical Summary Score: Change at Month 18 | -6.66 ± 17.340 |
| Clinical Summary Score: Change at Month 24 | -2.87 ± 15.875 |
| Clinical Summary Score: Change at Month 30 | -7.80 ± 17.497 |
| Clinical Summary Score: Change at Month 36 | -9.53 ± 17.700 |
| Clinical Summary Score: Change at Month 42 | -17.05 ± 22.804 |
| Clinical Summary Score: Change at Month 48 | -15.67 ± 24.854 |
| Clinical Summary Score: Change at Month 54 | -16.90 ± 21.295 |
| Clinical Summary Score: Change at Month 66 | -3.45 ± 27.219 |
| Clinical Summary Score: Change at Month 72 | -1.82 ± 21.558 |
| Clinical Summary Score: Change at Month 78 | -7.13 ± 22.422 |
| Clinical Summary Score: Change at Month 84 | -6.53 ± 29.881 |
| Clinical Summary Score: Change at Month 90 | -2.47 ± 24.198 |
| Clinical Summary Score: Change at Month 96 | -19.27 ± 42.768 |
| Clinical Summary Score: Change at Month 102 | -15.10 ± 31.690 |
| Clinical Summary Score: Change at Month 108 | -3.26 ± 27.764 |
| Clinical Summary Score: Change at Month 114 | -4.69 ± 32.213 |
| Clinical Summary Score: Change at Month 120 | -42.45 ± 11.417 |
| Clinical Summary Score: Change at Month 126 | -38.02 ± 14.731 |
| Clinical Summary Score: Change at Month 132 | -40.63 |
Echocardiography abnormalities included: absent respiratory variation of inferior vena cava, any valve thickening, aortic valve thickening, decreased respiratory variation of inferior vena cava, dilated inferior vena cava, E deceleration time less than or equal to (\<=) 150 millisecond, E wave/A Wave (E/A) ratio \>=2, ejection fraction \< 50%, isovolumic relaxation time (IVRT) \<=70 millisecond, left ventricular posterior wall thickness \>=13 millimeter (mm), left ventricular septal thickness \>= 13 mm, mitral valve thickening, pericardial effusion, pulmonary valve thickening, right ventricular thickness \>=7 mm, tricuspid valve thickening, ratio between early mitral inflow velocity and mitral annular early diastolic velocity (e/e') Lateral greater than (\>) 15, e/e' Septal \>15.
| Participants | Tafamidis 20 mg |
|---|---|
| Number of Participants With Abnormalities in Echocardiography | 31 |
Troponin I and troponin T are the cardiac markers. Troponin I and troponin T are part of the troponin complex, where troponin I is bound to actin in thin myofilaments and troponin T is bound to tropomyosin. Higher level of these markers is indicative of heart damage.
| nanogram per milliliter | Tafamidis 20 mg |
|---|---|
| Troponin I: Change at Month 6 | -0.016 ± 0.0533 |
| Troponin I: Change at Month 18 | 0.032 ± 0.1307 |
| Troponin I: Change at Month 24 | 0.023 ± 0.0986 |
| Troponin I: Change at Month 30 | 0.022 ± 0.1038 |
| Troponin I: Change at Month 36 | 0.029 ± 0.1099 |
| Troponin I: Change at Month 42 | 0.042 ± 0.1409 |
| Troponin I: Change at Month 48 | 0.058 ± 0.1409 |
| Troponin I: Change at Month 54 | 0.042 ± 0.1226 |
| Troponin I: Change at Month 66 | -0.012 ± 0.0133 |
| Troponin I: Change at Month 72 | -0.010 ± 0.0183 |
| Troponin I: Change at Month 78 | -0.013 ± 0.0208 |
| Troponin I: Change at Month 84 | -0.008 ± 0.0096 |
| Troponin I: Change at Month 90 | -0.003 ± 0.0293 |
| Troponin I: Change at Month 96 | -0.008 ± 0.0150 |
| Troponin I: Change at Month 102 | -0.010 ± 0.0356 |
| Troponin I: Change at Month 108 | 0.000 ± 0.0071 |
| Troponin I: Change at Month 114 | 0.000 ± 0.0271 |
| Troponin I: Change at Month 120 | 0.000 ± 0.0141 |
| Troponin I: Change at Month 126 | 0.005 ± 0.0354 |
| Troponin T: Change at Month 6 | -0.0007 ± 0.01710 |
| Troponin T: Change at Month 18 | 0.0271 ± 0.07429 |
| Troponin T: Change at Month 24 | 0.0132 ± 0.03286 |
| Troponin T: Change at Month 30 | 0.0166 ± 0.02227 |
| Troponin T: Change at Month 36 | 0.0205 ± 0.03049 |
| Troponin T: Change at Month 42 | 0.0329 ± 0.05665 |
| Troponin T: Change at Month 48 | 0.0510 ± 0.09562 |
| Troponin T: Change at Month 54 | 0.0562 ± 0.13264 |
| Troponin T: Change at Month 66 | 0.0050 ± 0.02588 |
| Troponin T: Change at Month 72 | -0.0055 ± 0.01714 |
| Troponin T: Change at Month 78 | 0.0000 ± 0.01732 |
| Troponin T: Change at Month 84 | -0.0003 ± 0.01415 |
| Troponin T: Change at Month 90 | 0.0026 ± 0.00962 |
| Troponin T: Change at Month 96 | -0.0037 ± 0.00551 |
| Troponin T: Change at Month 102 | 0.0098 ± 0.01461 |
| Troponin T: Change at Month 108 | 0.0100 ± 0.00707 |
| Troponin T: Change at Month114 | 0.0100 ± 0.00816 |
| Troponin T: Change at Month 120 | 0.0150 ± 0.02121 |
| Troponin T: Change at Month 126 | 0.0000 |
NT-proBNP was biomarker of cardiac stress (myocardial necrosis and increased filling pressures/ LV wall stress).
| nanogram per milliliter | Tafamidis 20 mg |
|---|---|
| Change at Month 6 | 66.0 ± 2164.66 |
| Change at Month 18 | 492.0 ± 2455.65 |
| Change at Month 24 | 211.5 ± 2119.01 |
| Change at Month 30 | 701.8 ± 2423.16 |
| Change at Month 36 | 1063.5 ± 2813.85 |
| Change at Month 42 | 2510.2 ± 5143.47 |
| Change at Month 48 | 3761.2 ± 7892.80 |
| Change at Month 54 | 1668.1 ± 2677.27 |
| Change at Month 66 | 433.3 ± 493.76 |
| Change at Month 72 | 625.5 ± 471.41 |
| Change at Month 78 | 707.7 ± 236.53 |
| Change at Month 84 | 348.5 ± 700.98 |
| Change at Month 90 | 283.7 ± 971.53 |
| Change at Month 96 | 1453.0 ± 2193.75 |
| Change at Month 102 | 1439.0 ± 2032.43 |
| Change at Month 108 | 346.4 ± 1279.58 |
| Change at Month 114 | 465.7 ± 790.48 |
| Change at Month 120 | 1232.0 ± 667.51 |
| Change at Month 126 | 1249.0 |
All cause hospitalization was defined as any serious adverse event, which resulted in hospitalization. Cardiac-related hospitalization was any hospitalization meeting the following criteria: cardiac disorders or AE preferred term as chest discomfort, chest pain, death, cerebrovascular accident, embolic stroke, disease progression.
| Participants | Tafamidis 20 mg |
|---|---|
| All-cause Hospitalization | 27 |
| Cardiac Related Hospitalization | 18 |
Time to death for all participants with a death date in Clinical Database, or censored at the last dose date + 28 days for those participants who were alive at the end of the study is reported.
| years | Tafamidis 20 mg |
|---|---|
| All-Cause Mortality | 4.1 (1.9 to 5.4) |
| Cardiac-related mortality | 5.9 (3.0 to NA) |
An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both serious and all non-serious adverse events.
| Participants | Tafamidis 20 mg |
|---|---|
| Participants with AEs | 31 |
| Participants with SAEs | 29 |
Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both serious and all non-serious adverse events. Relatedness to study drug was assessed by the investigator as (Yes/No).
| Participants | Tafamidis 20 mg |
|---|---|
| Participant with AEs | 7 |
| Participant with SAEs | 4 |
Physical examination included examination of general appearance, endocrine, head and neck, cardiovascular, eyes, abdomen, ears, skin, nose, musculoskeletal, throat, neurological, respiratory, immunologic/allergies, genitourinary, hematologic/lymphatic. Clinical significance of any physical examination finding was judged by investigator.
| Participants | Tafamidis 20 mg |
|---|---|
| Number of Participants With Clinically Significant Physical Examination Findings | 19 |
Number of participants who used medication other than study drug were reported.
| Participants | Tafamidis 20 mg |
|---|---|
| Number of Participants With Any Concomitant Medications | 31 |
ECG parameters included PR interval (millisecond), RR interval (millisecond), QRS interval (millisecond), QT and QTc interval (millisecond) and heart rate (beats per minute). Clinical significance of any ECG finding was judged by investigator.
| Participants | Tafamidis 20 mg |
|---|---|
| Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings | 1 |
Laboratory parameters included hematology and biochemistry: alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen, gamma glutamyl transferase (GGT), creatinine, total bilirubin, international normalized ratio (INR), troponin I, troponin T, prothrombin time, sodium, globulin potassium, chloride, bicarbonate, cholesterol, calcium, uric acid, inorganic phosphorous, thyroid-stimulating hormone, glucose, total thyroxine (T4), free T4, total proteins, prealbumin (transthyretin), albumin, hemoglobin, platelets, hematocrit, white blood cell count, red blood cell count, neutrophils, packed cell volume, lymphocytes, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, eosinophils, mean corpuscular hemoglobin concentration, basophils, retinol-binding protein, Urinalysis: bilirubin, pH, blood (free Hb), protein, nitrite, glucose, urobilinogen, ketones, specific gravity.
| Participants | Tafamidis 20 mg |
|---|---|
| Number of Participants With Laboratory Abnormalities | 27 |
Collected over Post-Month 12 up to Month 132 (approximately 10 years) of Study FX1B-303. Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tafamidis 20 mg | 23/31 (74.2%) | 29/31 (93.5%) | 30/31 (96.8%) |
| Event | Tafamidis 20 mg |
|---|---|
| CARDIAC FAILURE CONGESTIVECardiac disorders | 9/31 |
| CARDIAC FAILURECardiac disorders | 6/31 |
| FALLInjury, poisoning and procedural complications | 6/31 |
| FAMILIAL AMYLOIDOSISCongenital, familial and genetic disorders | 4/31 |
| CHEST PAINGeneral disorders | 3/31 |
| CELLULITISInfections and infestations | 3/31 |
| DEHYDRATIONMetabolism and nutrition disorders | 3/31 |
| ATRIAL TACHYCARDIACardiac disorders | 2/31 |
| FAECALOMAGastrointestinal disorders | 2/31 |
| ASTHENIAGeneral disorders | 2/31 |
| Event | Tafamidis 20 mg |
|---|---|
| FALLInjury, poisoning and procedural complications | 13/31 |
| CONSTIPATIONGastrointestinal disorders | 11/31 |
| BACK PAINMusculoskeletal and connective tissue disorders | 11/31 |
| FATIGUEGeneral disorders | 10/31 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 9/31 |
| DYSPNOEARespiratory, thoracic and mediastinal disorders | 9/31 |
| DEHYDRATIONMetabolism and nutrition disorders | 7/31 |
| PAIN IN EXTREMITYMusculoskeletal and connective tissue disorders | 7/31 |
| SKIN LACERATIONInjury, poisoning and procedural complications | 7/31 |
| URINARY TRACT INFECTIONInfections and infestations | 6/31 |
The intent to treat (ITT) population included all participants who were enrolled and received at least 1 dose of study medication, had baseline and at least 1 post-baseline cardiac measure.
| Age, Continuous(years) | Tafamidis 20 mg |
|---|---|
| Mean | 77.6 ± 4.89 |
| Sex: Female, Male(Participants) | Tafamidis 20 mg |
|---|---|
| Female | 3 |
| Male | 28 |
| Race/Ethnicity, Customized(Participants) | Tafamidis 20 mg |
|---|---|
| Caucasian | 27 |
| Afro-caribbean | 1 |
| African American | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Sep 2009 to primary completion in Nov 2019, 121 months.
Results were first posted in Jan 2021, 1 year 1 month after primary completion.
Of 20 phase 3 interventional studies under Cardiomyopathies, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 103. This study's 121 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tafamidis